8
Views
9
CrossRef citations to date
0
Altmetric
Original Article

The Efficacy of Ticarcillin-Clavulanate and Gentamkin as Emplrlc Treatment for Febrile Neutropenic Pediatric Patients with Cancer

, , &
Pages 181-187 | Received 14 May 1993, Accepted 16 Jul 1993, Published online: 09 Jul 2009
 

Abstract

The therapeutic efficacy of ticarcillin-clavulante and gentamicin was assessed in 56 pediatric cancer patients with 95 febrile neutropaic episodes. The mean temperature of these children on admission was 102°F (range 101° to 106°F), with a median absolute neutrophil count of 60. The median hospital stay was 7 days. All of the patients had one of two was of permanent central lines (Port-A-Cath, N = 75; Hickman, N = 20). Of 20 episodes of bacteremia,17 had microbial isolates that were gram-positive bacteria and 8 of these episodes required the addition of vamomycin. Clinical cure was achieved in 84 of the 95 febrile episodes (88%) with the use of ticarcillin-clavulante and gentamicin. There were no fatalities, nor were there any major toxicities. We conclude that the combination of ticarcillin-clavulanate and gentamicin is an effective initial empirical therapy for febrile neutropenic children with cancer. Gram-positive pathogens are the usual cause of breakthrough bacteremia in this clinical setting of central line usage, and associated morbidity and mortality from these organisms are low.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.